Drug intelligence / Profile preview

DR316

Development stage: Preclinical
Lead developer: Doer Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DR316 (also known as DR-316) is a preclinical-stage bispecific antibody (BsAb) developed by Doer Biologics. It simultaneously targets epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5). By co-targeting EGFR and LGR5, DR316 is designed to inhibit tumor cell proliferation and address cancer stem cell populations, which are often implicated in treatment resistance and tumor recurrence. The candidate is currently in the preclinical candidate (PCC) stage of development for the treatment of solid tumors.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5)

Beyond the preview

Go deeper on DR316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DR316.

Explore the full profile